Form 4: Medpace Director Schedules Future Stock Option Exercise

Medpace Holdings, Inc. Director Cornelius P. McCarthy III has scheduled the exercise of stock options to acquire 1,972 shares of common stock at $54.99 per share, effective July 22, 2025, under a Rule 10b5-1 plan.

Summary

• Cornelius P. McCarthy III, a Director of Medpace Holdings, Inc. (MEDP), reported a planned transaction under a Rule 10b5-1(c) plan.
• The transaction involves the exercise of stock options to acquire 1,972 shares of Medpace common stock.
• The exercise price for these shares is $54.99 per share.
• The transaction date is scheduled for July 22, 2025.
• Following this planned transaction, McCarthy III will beneficially own 11,859 shares of common stock.
• The stock option, which allows the right to buy shares at $54.99, vested in full on May 14, 2020, and is set to expire on May 17, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-planned insider transaction (option exercise) by a director. This is generally neutral, leaning slightly positive as it indicates the director is realizing value from their equity compensation, often implying confidence in the company's long-term performance, especially if the exercise price is significantly below current market value.

Positives

• The transaction is pre-planned under a Rule 10b5-1 plan, indicating a structured approach to insider trading and potentially reducing concerns about opportunistic timing.
• The exercise of options at a fixed price of $54.99 suggests the director is realizing value from previously granted equity compensation.

Future Outlook

The filing indicates a future scheduled transaction (July 22, 2025) under a Rule 10b5-1 plan, which is a pre-arranged trading plan designed to avoid insider trading accusations. It does not provide broader company future outlook.

Industry Context

This filing reports a routine insider equity transaction for a director of a contract research organization (CRO). Such transactions are common across all industries as part of executive compensation and personal financial planning.

Comparison to Industry Standards

• This is a standard insider transaction report (Form 4) for a director exercising stock options.
• The details of the option grant and exercise price are typical for equity compensation in the life sciences and healthcare services industry, similar to practices at comparable CROs like IQVIA Holdings Inc. (IQV) or Charles River Laboratories International, Inc. (CRL).

Corporate Governance

Stakeholder Impact

• The exercise of options results in a minor increase in outstanding shares, which is a negligible dilution for existing shareholders.
• It primarily impacts the director's personal equity holdings and compensation.

Key Dates

Keywords

Medpace Holdings, MEDP, Stock Option, Insider Trading, Form 4, Director, Equity, Share Acquisition, Rule 10b5-1